DOCSLIB.ORG

Supplementary Table 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SwissTargetPrediction Target Common Uniprot ChEMBL ID Target Class Probability* Known name ID actives (3D/2D) Protein phosphatase 2C PPM1B O75688 CHEMBL2845 Phosphatase 0.0714808399531 1 / 5 beta Protein-tyrosine PTPN1 P18031 CHEMBL335 Phosphatase 0.0714808399531 1 / 11 phosphatase 1B Serine/threonine PPP1CC P36873 CHEMBL4438 Phosphatase 0.0714808399531 1 / 5 protein phosphatase PP1-gamma catalytic subunit Serine/threonine- PPP5C Q9BPW0 CHEMBL1293265 Phosphatase 0.0619466223505 0 / 5 protein phosphatase Serine/threonine PPP1CA P62136 CHEMBL2164 Phosphatase 0.0619466223505 0 / 5 protein phosphatase PP1-alpha catalytic subunit Protein kinase C alpha PRKCA P17252 CHEMBL299 Kinase 0.0428942118511 0 / 29 Egl nine homolog 3 EGLN3 Q9H6Z9 CHEMBL5705 Enzyme 0.0428942118511 2 / 0 HMG-CoA reductase HMGCR P04035 CHEMBL402 Oxidoreductase 0.0428942118511 0 / 36 (by homology) Protein kinase C delta PRKCD Q05655 CHEMBL2996 Kinase 0.0428942118511 0 / 5 (by homology) 11-beta-hydroxysteroid HSD11B1 P28845 CHEMBL4235 Enzyme 0.0428942118511 0 / 12 dehydrogenase 1 UDP- UGT2B7 P16662 CHEMBL4370 Enzyme 0.0428942118511 0 / 6 glucuronosyltransferase 2B7 Carboxypeptidase A1 CPA1 P15085 CHEMBL2088 Protease 0.0428942118511 2 / 0 Mu opioid receptor OPRM1 P35372 CHEMBL233 Family A G 0.0428942118511 0 / 3 protein-coupled receptor Kappa Opioid receptor OPRK1 P41145 CHEMBL237 Family A G 0.0428942118511 0 / 18 protein-coupled receptor Mast cell CPA3 P15088 CHEMBL2645 Protease 0.0428942118511 2 / 0 carboxypeptidase A Carboxypeptidase B2 CPB2 Q96IY4 CHEMBL3419 Protease 0.0428942118511 1 / 0 isoform A Renin REN P00797 CHEMBL286 Protease 0.0428942118511 2 / 0 Cytochrome P450 19A1 CYP19A1 P11511 CHEMBL1978 Cytochrome 0.0428942118511 0 / 15 P450 DNA polymerase beta POLB P06746 CHEMBL2392 Enzyme 0.0 0 / 2 Hydroxycarboxylic acid HCAR2 Q8TDS4 CHEMBL3785 Family A G 0.0 6 / 0 receptor 2 protein-coupled receptor P-glycoprotein 1 ABCB1 P08183 CHEMBL4302 Primary active 0.0 0 / 12 transporter Solute carrier family 22 SLC22A6 Q4U2R8 CHEMBL1641347 Electrochemical 0.0 1 / 0 member 6 (by transporter homology) Dual specifcity CDC25A P30304 CHEMBL3775 Phosphatase 0.0 0 / 5 phosphatase Cdc25A Target Common Uniprot ChEMBL ID Target Class Probability* Known name ID actives (3D/2D) Serine/threonine- PIM1 P11309 CHEMBL2147 Kinase 0.0 2 / 0 protein kinase PIM1 Carbonic anhydrase XII CA12 O43570 CHEMBL3242 Lyase 0.0 9 / 0 Prolyl endopeptidase PREP P48147 CHEMBL3202 Protease 0.0 0 / 2 Glutamate FOLH1 Q04609 CHEMBL1892 Protease 0.0 7 / 0 carboxypeptidase II Hypoxia-inducible P4HTM Q9NXG6 CHEMBL3047 Enzyme 0.0 1 / 0 factor prolyl 4- hydroxylase Prostaglandin E PTGES O14684 CHEMBL5658 Enzyme 0.0 0 / 4 synthase Metabotropic glutamate GRM3 Q14832 CHEMBL2888 Family C G 0.0 0 / 1 receptor 3 protein-coupled receptor Metabotropic glutamate GRM2 Q14416 CHEMBL5137 Family C G 0.0 0 / 1 receptor 2 protein-coupled receptor Vitamin D receptor VDR P11473 CHEMBL1977 Nuclear 0.0 0 / 3 receptor Monoamine oxidase B MAOB P27338 CHEMBL2039 Oxidoreductase 0.0 5 / 0 Aldose reductase AKR1B1 P15121 CHEMBL1900 Enzyme 0.0 2 / 0 Kynurenine 3- KMO O15229 CHEMBL2145 Oxidoreductase 0.0 5 / 0 monooxygenase (by homology) Gamma-secretase PSEN2 P49810 CHEMBL2094135 Protease 0.0 0 / 5 PSENEN Q9NZ42 NCSTN Q92542 APH1A Q96BI3 PSEN1 P49768 APH1B Q8WW43 Aminopeptidase B RNPEP Q9H4A4 CHEMBL2432 Protease 0.0 2 / 0 Thrombin F2 P00734 CHEMBL204 Protease 0.0 0 / 11 Dihydroorotase CAD P27708 CHEMBL3093 Enzyme 0.0 2 / 0 G protein-coupled PTGDR2 Q9Y5Y4 CHEMBL5071 Family A G 0.0 3 / 0 receptor 44 protein-coupled receptor Transient receptor TRPV4 Q9HBA0 CHEMBL3119 Voltage-gated 0.0 0 / 1 potential cation channel ion channel subfamily V member 4 (by homology) Protein kinase C PRKCG P05129 CHEMBL2938 Kinase 0.0 0 / 3 gamma (by homology) Protein kinase C epsilon PRKCE Q02156 CHEMBL3582 Kinase 0.0 0 / 3 Protein kinase C eta PRKCH P24723 CHEMBL3616 Kinase 0.0 0 / 3 (by homology) Protein kinase C theta PRKCQ Q04759 CHEMBL3920 Kinase 0.0 0 / 4 Flap endonuclease 1 FEN1 P39748 CHEMBL5027 Enzyme 0.0 4 / 0 Farnesyl diphosphate FDPS P14324 CHEMBL1782 Transferase 0.0 1 / 0 synthase Lysine-specifc KDM4E B2RXH2 CHEMBL1293226 Eraser 0.0 2 / 0 demethylase 4D-like Aryl hydrocarbon AHR P35869 CHEMBL3201 Transcription 0.0 1 / 0 Target Common Uniprot ChEMBL ID Target Class Probability* Known name ID actives (3D/2D) receptor factor Serotonin 2b (5-HT2b) HTR2B P41595 CHEMBL1833 Family A G 0.0 0 / 2 receptor protein-coupled receptor Alpha-2a adrenergic ADRA2A P08913 CHEMBL1867 Family A G 0.0 0 / 1 receptor protein-coupled receptor Adrenergic receptor ADRA2C P18825 CHEMBL1916 Family A G 0.0 0 / 1 alpha-2 protein-coupled receptor Alpha-2b adrenergic ADRA2B P18089 CHEMBL1942 Family A G 0.0 0 / 1 receptor protein-coupled receptor Dopamine D1 receptor DRD1 P21728 CHEMBL2056 Family A G 0.0 0 / 1 protein-coupled receptor Dopamine D2 receptor DRD2 P14416 CHEMBL217 Family A G 0.0 0 / 1 protein-coupled receptor Alpha-1d adrenergic ADRA1D P25100 CHEMBL223 Family A G 0.0 0 / 1 receptor protein-coupled receptor Serotonin 2a (5-HT2a) HTR2A P28223 CHEMBL224 Family A G 0.0 0 / 2 receptor protein-coupled receptor Serotonin 2c (5-HT2c) HTR2C P28335 CHEMBL225 Family A G 0.0 0 / 2 receptor protein-coupled receptor Dopamine D3 receptor DRD3 P35462 CHEMBL234 Family A G 0.0 0 / 2 protein-coupled receptor Cytochrome P450 2D6 CYP2D6 P10635 CHEMBL289 Cytochrome 0.0 0 / 1 P450 Serotonin 6 (5-HT6) HTR6 P50406 CHEMBL3371 Family A G 0.0 0 / 2 receptor protein-coupled receptor Alpha-1a adrenergic ADRA1A P35348 CHEMBL229 Family A G 0.0 0 / 1 receptor (by protein-coupled homology) receptor Serotonin 1b (5-HT1b) HTR1B P28222 CHEMBL1898 Family A G 0.0 0 / 1 receptor (by protein-coupled homology) receptor Monoamine oxidase A MAOA P21397 CHEMBL1951 Oxidoreductase 0.0 2 / 0 Carbonic anhydrase VII CA7 P43166 CHEMBL2326 Lyase 0.0 3 / 0 Carbonic anhydrase III CA3 P07451 CHEMBL2885 Lyase 0.0 1 / 0 Carbonic anhydrase XIV CA14 Q9ULX7 CHEMBL3510 Lyase 0.0 3 / 0 Carbonic anhydrase IV CA4 P22748 CHEMBL3729 Lyase 0.0 1 / 0 Carbonic anhydrase VA CA5A P35218 CHEMBL4789 Lyase 0.0 2 / 0 Lysine-specifc KDM7A Q6ZMT4 CHEMBL2163177 Eraser 0.0 1 / 0 demethylase 7A/7B Monocarboxylate SLC16A1 P53985 CHEMBL4360 Electrochemical 0.0 3 / 0 transporter 1 (by transporter homology) Target Common Uniprot ChEMBL ID Target Class Probability* Known name ID actives (3D/2D) Carboxylesterase 2 CES2 O00748 CHEMBL3180 Enzyme 0.0 0 / 4 Heat shock protein HSP HSP90AA1 P07900 CHEMBL3880 Other cytosolic 0.0 1 / 0 90-alpha protein Estradiol 17-beta- HSD17B3 P37058 CHEMBL4234 Enzyme 0.0 0 / 12 dehydrogenase 3 Carbonic anhydrase VB CA5B Q9Y2D0 CHEMBL3969 Lyase 0.0 1 / 0 DNA excision repair ERCC5 P28715 CHEMBL4736 Other nuclear 0.0 2 / 0 protein ERCC-5 protein G-protein coupled GPR35 Q9HC97 CHEMBL1293267 Family A G 0.0 1 / 0 receptor 35 protein-coupled receptor D-amino-acid oxidase DAO P14920 CHEMBL5485 Enzyme 0.0 2 / 0 D-aspartate oxidase DDO Q99489 CHEMBL5887 Oxidoreductase 0.0 1 / 0 Carnitine O- CPT1A P50416 CHEMBL1293194 Enzyme 0.0 0 / 4 palmitoyltransferase 1, liver isoform (by homology) Glucose transporter SLC2A1 P11166 CHEMBL2535 Electrochemical 0.0 0 / 1 transporter Brain adenylate cyclase ADCY1 Q08828 CHEMBL2899 Enzyme 0.0 0 / 1 1 Lysine-specifc KDM4A O75164 CHEMBL5896 Eraser 0.0 1 / 0 demethylase 4A Lysine-specifc KDM4D Q6B0I6 CHEMBL6138 Eraser 0.0 1 / 0 demethylase 4D Lysine-specifc KDM4C Q9H3R0 CHEMBL6175 Eraser 0.0 1 / 0 demethylase 4C Protein FNTA P49354 CHEMBL2094108 Enzyme 0.0 0 / 5 farnesyltransferase FNTB P49356 Squalene synthetase FDFT1 P37268 CHEMBL3338 Enzyme 0.0 0 / 2 (by homology) T-cell protein-tyrosine PTPN2 P17706 CHEMBL3807 Phosphatase 0.0 0 / 2 phosphatase Aldehyde reductase AKR1A1 P14550 CHEMBL2246 Enzyme 0.0 1 / 0 (by homology) Platelet activating PTAFR P25105 CHEMBL250 Family A G 0.0 0 / 4 factor receptor (by protein-coupled homology) receptor Cyclooxygenase-1 PTGS1 P23219 CHEMBL221 Oxidoreductase 0.0 1 / 0 Serine-protein kinase ATM Q13315 CHEMBL3797 Kinase 0.0 0 / 1 ATM Nuclear receptor ROR- RORC P51449 CHEMBL1741186 Nuclear 0.0 0 / 1 gamma receptor Methionine METAP2 P50579 CHEMBL3922 Protease 0.0 0 / 4 aminopeptidase 2 Toll-like receptor (TLR7/ TLR9 Q9NR96 CHEMBL5804 Toll-like and Il-1 0.0 0 / 2 TLR9) receptors NAD-dependent SIRT2 Q8IXJ6 CHEMBL4462 Eraser 0.0 0 / 1 deacetylase sirtuin 2 Trypsin I PRSS1 P07477 CHEMBL209 Protease 0.0 0 / 8 Chymotrypsin C CTRC Q99895 CHEMBL2386 Protease 0.0 0 / 3 Target Common Uniprot ChEMBL ID Target Class Probability* Known name ID actives (3D/2D) 11-beta-hydroxysteroid HSD11B2 P80365 CHEMBL3746 Enzyme 0.0 0 / 2 dehydrogenase 2 (by homology) Carbonic anhydrase II CA2 P00918 CHEMBL205 Lyase 0.0 19 / 1 .
Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB

    Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB

    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
  • Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids

    Supplementary Materials: Evaluation of Cytotoxicity and Α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids

    Supplementary Materials: Evaluation of cytotoxicity and α-glucosidase inhibitory activity of amide and polyamino-derivatives of lupane triterpenoids Oxana B. Kazakova1*, Gul'nara V. Giniyatullina1, Akhat G. Mustafin1, Denis A. Babkov2, Elena V. Sokolova2, Alexander A. Spasov2* 1Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences, 71, pr. Oktyabrya, 450054 Ufa, Russian Federation 2Scientific Center for Innovative Drugs, Volgograd State Medical University, Novorossiyskaya st. 39, Volgograd 400087, Russian Federation Correspondence Prof. Dr. Oxana B. Kazakova Ufa Institute of Chemistry of the Ufa Federal Research Centre of the Russian Academy of Sciences 71 Prospeсt Oktyabrya Ufa, 450054 Russian Federation E-mail: [email protected] Prof. Dr. Alexander A. Spasov Scientific Center for Innovative Drugs of the Volgograd State Medical University 39 Novorossiyskaya st. Volgograd, 400087 Russian Federation E-mail: [email protected] Figure S1. 1H and 13C of compound 2. H NH N H O H O H 2 2 Figure S2. 1H and 13C of compound 4. NH2 O H O H CH3 O O H H3C O H 4 3 Figure S3. Anticancer screening data of compound 2 at single dose assay 4 Figure S4. Anticancer screening data of compound 7 at single dose assay 5 Figure S5. Anticancer screening data of compound 8 at single dose assay 6 Figure S6. Anticancer screening data of compound 9 at single dose assay 7 Figure S7. Anticancer screening data of compound 12 at single dose assay 8 Figure S8. Anticancer screening data of compound 13 at single dose assay 9 Figure S9. Anticancer screening data of compound 14 at single dose assay 10 Figure S10.
  • The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome Is Evolutionarily Conserved

    The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome Is Evolutionarily Conserved

    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.28.317750; this version posted September 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The Global Architecture Shaping the Heterogeneity and Tissue-Dependency of the MHC Class I Immunopeptidome is Evolutionarily Conserved Authors Peter Kubiniok†1, Ana Marcu†2,3, Leon Bichmann†2,4, Leon Kuchenbecker4, Heiko Schuster1,5, David Hamelin1, Jérome Despault1, Kevin Kovalchik1, Laura Wessling1, Oliver Kohlbacher4,7,8,9,10 Stefan Stevanovic2,3,6, Hans-Georg Rammensee2,3,6, Marian C. Neidert11, Isabelle Sirois1, Etienne Caron1,12* Affiliations *Corresponding and Leading author: Etienne Caron ([email protected]) †Equal contribution to this work 1CHU Sainte-Justine Research Center, Montreal, QC H3T 1C5, Canada 2Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 3Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Baden-Württemberg, 72076, Germany. 4Applied Bioinformatics, Dept. of Computer Science, University of Tübingen, Tübingen, Baden- Württemberg, 72074, Germany. 5Immatics Biotechnologies GmbH, Tübingen, 72076, Baden-Württemberg, Germany. 6DKFZ Partner Site Tübingen, German Cancer Consortium (DKTK), Tübingen, Baden- Württemberg, 72076, Germany. 7Institute for Bioinformatics and Medical Informatics,
  • Interplay Between Epigenetics and Metabolism in Oncogenesis: Mechanisms and Therapeutic Approaches

    Interplay Between Epigenetics and Metabolism in Oncogenesis: Mechanisms and Therapeutic Approaches

    OPEN Oncogene (2017) 36, 3359–3374 www.nature.com/onc REVIEW Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches CC Wong1, Y Qian2,3 and J Yu1 Epigenetic and metabolic alterations in cancer cells are highly intertwined. Oncogene-driven metabolic rewiring modifies the epigenetic landscape via modulating the activities of DNA and histone modification enzymes at the metabolite level. Conversely, epigenetic mechanisms regulate the expression of metabolic genes, thereby altering the metabolome. Epigenetic-metabolomic interplay has a critical role in tumourigenesis by coordinately sustaining cell proliferation, metastasis and pluripotency. Understanding the link between epigenetics and metabolism could unravel novel molecular targets, whose intervention may lead to improvements in cancer treatment. In this review, we summarized the recent discoveries linking epigenetics and metabolism and their underlying roles in tumorigenesis; and highlighted the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these abnormalities in cancer. Oncogene (2017) 36, 3359–3374; doi:10.1038/onc.2016.485; published online 16 January 2017 INTRODUCTION metabolic genes have also been identified as driver genes It has been appreciated since the early days of cancer research mutated in some cancers, such as isocitrate dehydrogenase 1 16 17 that the metabolic profiles of tumor cells differ significantly from and 2 (IDH1/2) in gliomas and acute myeloid leukemia (AML), 18 normal cells. Cancer cells have high metabolic demands and they succinate dehydrogenase (SDH) in paragangliomas and fuma- utilize nutrients with an altered metabolic program to support rate hydratase (FH) in hereditary leiomyomatosis and renal cell 19 their high proliferative rates and adapt to the hostile tumor cancer (HLRCC).
  • Mutant IDH, (R)-2-Hydroxyglutarate, and Cancer

    Mutant IDH, (R)-2-Hydroxyglutarate, and Cancer

    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer Julie-Aurore Losman1 and William G. Kaelin Jr.1,2,3 1Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA; 2Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA Mutations in metabolic enzymes, including isocitrate whether altered cellular metabolism is a cause of cancer dehydrogenase 1 (IDH1) and IDH2, in cancer strongly or merely an adaptive response of cancer cells in the face implicate altered metabolism in tumorigenesis. IDH1 of accelerated cell proliferation is still a topic of some and IDH2 catalyze the interconversion of isocitrate and debate. 2-oxoglutarate (2OG). 2OG is a TCA cycle intermediate The recent identification of cancer-associated muta- and an essential cofactor for many enzymes, including tions in three metabolic enzymes suggests that altered JmjC domain-containing histone demethylases, TET cellular metabolism can indeed be a cause of some 5-methylcytosine hydroxylases, and EglN prolyl-4-hydrox- cancers (Pollard et al. 2003; King et al. 2006; Raimundo ylases. Cancer-associated IDH mutations alter the enzymes et al. 2011). Two of these enzymes, fumarate hydratase such that they reduce 2OG to the structurally similar (FH) and succinate dehydrogenase (SDH), are bone fide metabolite (R)-2-hydroxyglutarate [(R)-2HG]. Here we tumor suppressors, and loss-of-function mutations in FH review what is known about the molecular mechanisms and SDH have been identified in various cancers, in- of transformation by mutant IDH and discuss their im- cluding renal cell carcinomas and paragangliomas.
  • Common Gene Polymorphisms Associated with Thrombophilia

    Common Gene Polymorphisms Associated with Thrombophilia

    Chapter 5 Common Gene Polymorphisms Associated with Thrombophilia Christos Yapijakis, Zoe Serefoglou and Constantinos Voumvourakis Additional information is available at the end of the chapter http://dx.doi.org/10.5772/61859 Abstract Genetic association studies have revealed a correlation between DNA variations in genes encoding factors of the hemostatic system and thrombosis-related disease. Certain var‐ iant alleles of these genes that affect either gene expression or function of encoded protein are known to be genetic risk factors for thrombophilia. The chapter presents the current genetics and molecular biology knowledge of the most important DNA polymorphisms in thrombosis-related genes encoding coagulation factor V (FV), coagulation factor II (FII), coagulation factor XII (FXII), coagulation factor XIII A1 subunit (FXIIIA1), 5,10- methylene tetrahydrofolate reductase (MTHFR), serpine1 (SERPINE1), angiotensin I-con‐ verting enzyme (ACE), angiotensinogen (AGT), integrin A2 (ITGA2), plasma carboxypeptidase B2 (CPB2), platelet glycoprotein Ib α polypeptide (GP1BA), thrombo‐ modulin (THBD) and protein Z (PROZ). The molecular detection methods of each DNA polymorphism is presented, in addition to the current knowledge regarding its influence on thrombophilia and related thrombotic events, including stroke, myocardial infarction, deep vein thrombosis, spontaneous abortion, etc. In addition, best thrombosis prevention strategies with a combination of genetic counseling and molecular testing are discussed. Keywords: Thrombophilia, coagulation
  • Gene PMID WBS Locus ABR 26603386 AASDH 26603386

    Gene PMID WBS Locus ABR 26603386 AASDH 26603386

    Supplementary material J Med Genet Gene PMID WBS Locus ABR 26603386 AASDH 26603386 ABCA1 21304579 ABCA13 26603386 ABCA3 25501393 ABCA7 25501393 ABCC1 25501393 ABCC3 25501393 ABCG1 25501393 ABHD10 21304579 ABHD11 25501393 yes ABHD2 25501393 ABHD5 21304579 ABLIM1 21304579;26603386 ACOT12 25501393 ACSF2,CHAD 26603386 ACSL4 21304579 ACSM3 26603386 ACTA2 25501393 ACTN1 26603386 ACTN3 26603386;25501393;25501393 ACTN4 21304579 ACTR1B 21304579 ACVR2A 21304579 ACY3 19897463 ACYP1 21304579 ADA 25501393 ADAM12 21304579 ADAM19 25501393 ADAM32 26603386 ADAMTS1 25501393 ADAMTS10 25501393 ADAMTS12 26603386 ADAMTS17 26603386 ADAMTS6 21304579 ADAMTS7 25501393 ADAMTSL1 21304579 ADAMTSL4 25501393 ADAMTSL5 25501393 ADCY3 25501393 ADK 21304579 ADRBK2 25501393 AEBP1 25501393 AES 25501393 AFAP1,LOC84740 26603386 AFAP1L2 26603386 AFG3L1 21304579 AGAP1 26603386 AGAP9 21304579 Codina-Sola M, et al. J Med Genet 2019; 56:801–808. doi: 10.1136/jmedgenet-2019-106080 Supplementary material J Med Genet AGBL5 21304579 AGPAT3 19897463;25501393 AGRN 25501393 AGXT2L2 25501393 AHCY 25501393 AHDC1 26603386 AHNAK 26603386 AHRR 26603386 AIDA 25501393 AIFM2 21304579 AIG1 21304579 AIP 21304579 AK5 21304579 AKAP1 25501393 AKAP6 21304579 AKNA 21304579 AKR1E2 26603386 AKR7A2 21304579 AKR7A3 26603386 AKR7L 26603386 AKT3 21304579 ALDH18A1 25501393;25501393 ALDH1A3 21304579 ALDH1B1 21304579 ALDH6A1 21304579 ALDOC 21304579 ALG10B 26603386 ALG13 21304579 ALKBH7 25501393 ALPK2 21304579 AMPH 21304579 ANG 21304579 ANGPTL2,RALGPS1 26603386 ANGPTL6 26603386 ANK2 21304579 ANKMY1 26603386 ANKMY2
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS Et Al

    US 2016.0346364A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS et al. (43) Pub. Date: Dec. 1, 2016 (54) MEDICAMENT AND METHOD FOR (52) U.S. Cl. TREATING INNATE IMMUNE RESPONSE CPC ........... A61K 38/488 (2013.01); A61K 38/482 DISEASES (2013.01); C12Y 304/23019 (2013.01); C12Y 304/21026 (2013.01); C12Y 304/23018 (71) Applicant: DSM IPASSETS B.V., Heerlen (NL) (2013.01); A61K 9/0053 (2013.01); C12N 9/62 (2013.01); A23L 29/06 (2016.08); A2ID 8/042 (72) Inventors: Maaike Johanna BRUINS, Kaiseraugst (2013.01); A23L 5/25 (2016.08); A23V (CH); Luppo EDENS, Kaiseraugst 2002/00 (2013.01) (CH); Lenneke NAN, Kaiseraugst (CH) (57) ABSTRACT (21) Appl. No.: 15/101,630 This invention relates to a medicament or a dietary Supple (22) PCT Filed: Dec. 11, 2014 ment comprising the Aspergillus niger aspergilloglutamic peptidase that is capable of hydrolyzing plant food allergens, (86). PCT No.: PCT/EP2014/077355 and more particularly, alpha-amylase/trypsin inhibitors, thereby treating diseases due to an innate immune response S 371 (c)(1), in humans, and/or allowing to delay the onset of said (2) Date: Jun. 3, 2016 diseases. The present invention relates to the discovery that (30) Foreign Application Priority Data the Aspergillus niger aspergilloglutamic peptidase is capable of hydrolyzing alpha-amylase/trypsin inhibitors that are Dec. 11, 2013 (EP) .................................. 13196580.8 present in wheat and related cereals said inhibitors being strong inducers of innate immune response. Furthermore, Publication Classification the present invention relates to a method for hydrolyzing alpha-amylase/trypsin inhibitors comprising incubating a (51) Int.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders

    Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders

    Hindawi Publishing Corporation Autism Research and Treatment Volume 2012, Article ID 868576, 6 pages doi:10.1155/2012/868576 Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders Naghi Momeni,1 Lars Brudin,2 Fatemeh Behnia,3 Berit Nordstrom,¨ 4 Ali Yosefi-Oudarji,5 Bengt Sivberg,4 Mohammad T. Joghataei,5 and Bengt L. Persson1 1 School of Natural Sciences, Linnaeus University, 39182 Kalmar, Sweden 2 Department of Clinical Physiology, Kalmar County Hospital, 39185 Kalmar, Sweden 3 Department of Occupational Therapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 4 Department of Health Sciences, Autism Research, Faculty of Medicine, Lund University, Box 157, 22100 Lund, Sweden 5 Cellular and Molecular Research Centre, Tehran University of Medical Sciences (TUMS), Tehran, Iran Correspondence should be addressed to Bengt Sivberg, [email protected] Received 17 June 2011; Revised 22 August 2011; Accepted 22 August 2011 Academic Editor: Judy Van de Water Copyright © 2012 Naghi Momeni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Autism spectrum disorders (ASDs) are neurodevelopmental and behavioural syndromes affecting social orientation, behaviour, and communication that can be classified as developmental disorders. ASD is also associated with immune system abnormality. Im- mune system abnormalities may be caused partly by complement system factor I deficiency. Complement factor I is a serine pro- tease present in human plasma that is involved in the degradation of complement protein C3b, which is a major opsonin of the complement system.
  • Endothelial Cell Injury in Atherosclerosis Is Regulated by Glycolysis (Review)

    Endothelial Cell Injury in Atherosclerosis Is Regulated by Glycolysis (Review)

    INTERNATIONAL JOURNAL OF MOleCular meDICine 47: 65-76, 2021 Mechanism overview and target mining of atherosclerosis: Endothelial cell injury in atherosclerosis is regulated by glycolysis (Review) RUIYING WANG1-5, MIN WANG1-5, JINGXUE YE1-5, GUIBO SUN1-5 and XIAOBO SUN1-5 1Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 2Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 3Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 4Key Laboratory of Efficacy Evaluation of Chinese Medicine Against Glycolipid Metabolic Disorders, State Administration of Traditional Chinese Medicine, Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences; 5Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Chinese Academy of Medical Sciences, Beijing 100193, P.R. China Received August 14, 2020; Accepted November 5, 2020 DOI: 10.3892/ijmm.2020.4798 Abstract. Atherosclerosis (AS) is a chronic disease with a In conclusion, endothelial cell injury in AS may be alleviated by complex pathology that may lead to several cardiovascular and glycolysis and is a potential clinical treatment strategy for AS. cerebrovascular diseases; however, further research is neces- sary to fully elucidate its pathogenesis. The main risk factors for AS include lipid metabolism disorders, endothelial cell Contents injury, inflammation and immune dysfunction, among which vascular endothelial cell damage is considered as the main 1.
  • Serine Proteases with Altered Sensitivity to Activity-Modulating

    Serine Proteases with Altered Sensitivity to Activity-Modulating

    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.